典型文献
Tenofovir
vs. entecavir on recurrence of hepatitis B virus-related hepatocellular carcinoma beyond Milan criteria after hepatectomy
文献摘要：
Background::Hepatectomy for hepatocellular carcinoma (HCC) beyond the Milan criteria is shown to be beneficial. However, a high rate of post-operative HCC recurrence hinders the long-term survival of the patients. This study aimed to investigate and compare the impacts of tenofovir (TDF) and entecavir (ETV) on the recurrence of hepatitis B viral (HBV)-related HCC beyond the Milan criteria.Methods::Data pertaining to 1532 patients who underwent hepatectomy and received antiviral therapy between January 2014 and January 2019 were collected from five centers. Recurrence-free survival (RFS) analysis was performed using the Kaplan-Meier method. Cox proportional hazards regression analysis was performed to determine prognostic factors for HCC recurrence.Results::The analysis incorporates 595 HBV-related HCC patients. The overall 5-year RFS was 21.3%. Among them, 533 and 62 patients received ETV and TDF treatment, respectively. The 1-, 3-, and 5-year RFS rates were 46.3%, 27.4%, and 19.6%, respectively, in the ETV group compared with 65.1%, 41.8%, and 37.2%, respectively, in the TDF group (
P < 0.001). Multivariate analysis showed that TDF treatment (hazard ratio [HR]: 0.604,
P = 0.005), cirrhosis (HR: 1.557,
P = 0.004), tumor size (HR: 1.037,
P = 0.008), microvascular invasion (MVI) (HR: 1.403,
P = 0.002), portal vein tumor thrombus (PVTT) (HR: 1.358,
P = 0.012), capsular invasion (HR: 1.228,
P= 0.040), and creatinine levels (CREA) (HR: 0.993,
P = 0.031) were statistically significant prognostic factors associated with RFS.
Conclusions::Patients with HCC beyond the Milan criteria exhibited a high rate of HCC recurrence after hepatectomy. Compared to the ETV therapy, TDF administration significantly lowered the risk of HCC recurrence.
文献关键词：
Hepatocellular carcinoma;Hepatitis B virus;Antiviral drugs;Recurrence;Hepatectomy
中图分类号：
作者姓名：
Shen Junyi;Qi Weili;Dai Junlong;Leng Shusheng;Jiang Kangyi;Zhang Yu;Ran Shun;Li Chuan;Wen Tianfu
作者机构：
Department of Liver Surgery and Liver Transplantation Center, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China;Laboratory of Liver Transplantation, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China;Institute of Clinical Pathology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China;Department of Hepatobiliary and Pancreatic Surgery, The Affiliated Hospital of Chengdu University, Chengdu, Sichuan 610072, China;Department of Hepatobiliary and Pancreatic Surgery, The People's Hospital of Leshan, Leshan, Sichuan 614700, China;Department of Hepatobiliary Surgery, Sichuan Provincial People's Hospital, Chinese Academy of Sciences, Chengdu, Sichuan 610072, China;Department of Hepatobiliary Surgery, Affiliated Cancer Hospital of Guizhou Medical University, Guiyang, Guizhou 550000, China
文献出处：
引用格式：
[1]Shen Junyi;Qi Weili;Dai Junlong;Leng Shusheng;Jiang Kangyi;Zhang Yu;Ran Shun;Li Chuan;Wen Tianfu-.Tenofovir
vs. entecavir on recurrence of hepatitis B virus-related hepatocellular carcinoma beyond Milan criteria after hepatectomy
)[J].中华医学杂志（英文版）,2022(03):301-308
A类：
hepatectomy
B类：
Tenofovir,entecavir,recurrence,hepatitis,virus,related,hepatocellular,carcinoma,beyond,Milan,criteria,after,Background,Hepatectomy,HCC,shown,beneficial,However,high,post,operative,hinders,long,survival,patients,This,study,aimed,investigate,impacts,tenofovir,TDF,ETV,HBV,Methods,Data,pertaining,who,underwent,received,antiviral,therapy,between,January,collected,from,five,centers,Recurrence,free,RFS,analysis,was,performed,using,Kaplan,Meier,method,Cox,proportional,hazards,regression,determine,prognostic,factors,Results,incorporates,overall,year,Among,them,treatment,respectively,group,compared,Multivariate,showed,that,cirrhosis,tumor,size,microvascular,invasion,MVI,portal,vein,thrombus,PVTT,capsular,creatinine,levels,CREA,statistically,associated,Conclusions,Patients,exhibited,Compared,administration,significantly,lowered,risk,Hepatocellular,Hepatitis,Antiviral,drugs
AB值：
0.501762
相似文献
机标中图分类号，由域田数据科技根据网络公开资料自动分析生成，仅供学习研究参考。
